Ticker Launch

SPAC · Merger completed

CM Life Sciences, Inc.

Business combination with Mount Sinai Genomics, Inc. d/b/a Sema4

CM Life Sciences, Inc. is a blank-check company (SPAC) that raised $150M in its initial public offering on Sep 3, 2020, listing on Nasdaq Capital Market. It completed its business combination with Mount Sinai Genomics, Inc. d/b/a Sema4 on Jul 22, 2021; the combined company is Sema4 Holdings Corp. (SMFR). Sony led the IPO, with Soup and DowDuPont. White & Case advised the SPAC and Skadden, Arps advised the underwriters on the IPO.

Status
Merger completed
IPO date
Sep 3, 2020
IPO size
$150M
IPO exchange
Nasdaq Capital Market
Target
Mount Sinai Genomics, Inc. d/b/a Sema4
Announced
Feb 11, 2021
Closed
Jul 22, 2021
Combined company
Sema4 Holdings Corp. (SMFR)
IPO underwriters
Sony, Soup, DowDuPont, Highbridge Capital, Oak Hill Capital, Lazard, Google, Clover Health and Oscar Insurance
SPAC counsel (IPO)
White & Case
Underwriters' counsel (IPO)
Skadden, Arps

More on this SPAC for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Then $99/month or $999/year. Cancel anytime.

Filings

Other deSPACs that closed in 2021